Blue Horseshoe Stocks: SVSN Review & More

Stereo Vision Entertainment, Inc. SVSN

It was roughly six weeks back that we put SVSN on our radars on a routine news scan, and as we always say, it’s better to be early to the party than late. All the way up until last week, the stock wasn’t trading with any real vigor, but things have picked in a huge way, both in volume and price.

From its low at .08 at the beginning of last week, the stock finished out at a high of .89, for an intraweek rip of 1012% This came on the news that the company will file a $50M Real Estate Investment Trust on behalf of its CannaVision subsidiary, with the goal of organically growing cannabis for the purposes of extracting CBD.


Progressive Care, Inc. RXMD

We also want to swing back around to RXMD this morning, which we intially tagged onthe morning of February 22nd. Since that time the stock has exhibited a fairly steady climb up the chart.

We observed a low of .0663 in RXMD on that first day, and as of Friday’s new high of .129, we had watched as the stock rose 95% over a period of just seven trading sessions. It’s streaking to its highest PPS in nearly five years, so it’s safe to say RXMD is in blue sky breakout territory, and we’ll be eager to continue tracking its movements.



Fate Therapeutics, Inc. FATE

We also wanted to recap the solid move we’ve witnessed in FATE, since mentioning the stock toward the end of January. It dipped slightly to a low of 6.76 shortly thereafter, and has since gone a very impressive run.

The stock reached a new high of 14.02 on Friday, which worked out to a 108% upswing in a matter of less than a month.


Extended Watchlist:
RJDG, ATNM, INPX, NSPR, GNL, OTIV, CLSD, MYSZ

Blue Horseshoe Stocks: DAL, GALT Updates & More


Delta Air Lines, Inc. DAL  – Options Recap

We followed a range of Delta options beginning on Thursday morning, when we signaled the DAL Weekly $57-58 Calls in the wake of the company’s across-the-board Q4 earnings beat. We were glad to report on Friday that in a single session those three sets of contracts yielded gains ranging from roughly 780% to 1980%

Despite making such big moves already, Friday’s session brought more success for our tracked calls, so we wanted to open up this short trading week with a final recap on the maximum gains allowed by those excellent weekly contracts. The total ranges we observed over just two sessions were amazing.

$57 Calls – Range: .24-3.44 – Max Gain: 1313%
$57.50 Calls – Range: .14-2.96 – Max Gain: 2014%
$58 Calls – Range: .06-2.40 – Max Gain: 3900%


Galectin Therapeutics, Inc. GALT

We also want to swing back around for GALT, a stock we routinely tracked throughout 2017. It finished off that yea with a bang, and has continued its excellent run into 2018.

From lows it saw at the beginning of December at 1.28, to the new highs it made at the end of last week at 6.15 , GALT had executed a 380% increase in roughly five weeks!


Extended Watchlist:
NCTY, HEB, BB, OSIS, OTIV, HAWK

Blue Horseshoe Stocks: TEUM Update & More

Pareteum Corp. TEUM

The last time we mentioned TEUM was December 8th, shortly after which time the stock was trading for as little as .661. At the time the company had no involvement in the trendy cryptocurrency space.

Flash forward to this week, and an announcement that the company is adding blockchain capability for cryptocurrency support on its global cloud billing platform has the stock soaring to new highs.

TEUM hit 3.15 yesterday, which marks an increase of 377% in less than three weeks’ time. Volume for the day was on the order of roughly five times the monthly average.

Bitcoin itself has been making a nice rebound after the pullback which followed its big run to nearly $20K, and there is no reason to suspect that the push toward blockchain related technologies, both cryptocurrency and otherwise, is just a passing fad.


INSYS Therapeutics, Inc. INSY – Options Recap

We made our interest in the INSY 01/19 $8 & $9 Calls known yesterday morning, and it barely took any time at all for our ideas to come to fruition.

As we were mentioning yesterday, the company recently initiated Phase II trials of its synthetic Cannabidiol (CBD) Oral Solution for Treatment of Refractory Childhood Absence Epilepsy, and the FDA granted Fast Track status to the ‘drug’ for the treatment of a rare genetic disorder (Prader-Willi).

This news allowed for some very nice moves in our designated contracts. The $8 Calls ran from .35-1.00 for a gain of 186%, while the $9’s traded up from .20-.55, trending up 175% on the day.


Ampio Pharmaceuticals, Inc. AMPE

We also want to swing back to remind our readers of last week’s alert on AMPE. We tagged this play seven days ago (four trading days), and saw it trading for as little as 2.57. As of yesterday’s high of 3.55, the stock had thus far risen by 38%

The stock’s peak PPS represented a new annual high, so we’ll be interested to see how the stock performs in blue skies.


Extended Watchlist:
OTIV, FH, NETE, LFIN, GROW, IDXG, WATT, ATNM